Tirzepatide 15mg

Tirzepatide: A Dual-Action GLP-1 and GIP Receptor Agonist for Diabetes and Weight Loss

Tirzepatide (also known as LY3298176) is a novel unimolecular dual receptor agonist targeting both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently under investigation for its potential benefits in glycemic control and weight management [1, 2, 3].

Based on the human GIP hormone, tirzepatide is composed of 39 amino acids and includes a C20 fatty di-acid moiety, which prolongs its action and supports once-weekly dosing in humans [1, 2, 3].

After extensive clinical trials, tirzepatide was approved by the U.S. Food and Drug Administration (FDA) in May 2022 as a treatment for type 2 diabetes (T2D). It became the first FDA-approved dual GLP-1 and GIP receptor agonist for T2D management [4, 5].

In addition to its diabetes approval, tirzepatide is being studied for its weight loss effects in adults with a body mass index (BMI) of 27 or higher. Early results suggest significant and sustained weight management benefits [6, 7].

While it is now an FDA-approved medication for T2D, tirzepatide is also available to credentialed researchers studying its novel dual-agonist properties.

What Does Tirzepatide Do?

Tirzepatide is a powerful agent for controlling both blood sugar and body weight due to its dual action on GLP-1 and GIP receptors. Research has shown that its combined receptor agonism leads to a synergistic effect, resulting in a significantly enhanced insulin response and glucagon suppression, compared to therapies using either GIP or GLP-1 alone [3, 5].

GLP-1 and GIP are incretin hormones released by the intestine in response to food intake, stimulating insulin secretion from pancreatic beta cells [8]. Tirzepatide binds to the GIP receptor with similar affinity as native GIP but has about five times lower affinity for the GLP-1 receptor compared to native GLP-1. Interestingly, tirzepatide shows a preference for activating cAMP signaling over beta-arrestin recruitment at the GLP-1 receptor [9].

This biased agonism at the GLP-1 receptor is thought to contribute to tirzepatide’s effectiveness in stimulating insulin secretion [5]. Clinical trials have confirmed that tirzepatide is not only more effective than many existing treatments for T2D but also has a comparable safety profile [10, 11, 12, 13, 14].

Additionally, tirzepatide has been shown to increase adiponectin, an adipokine that plays a key role in regulating both lipid and glucose metabolism. Elevated adiponectin levels are associated with weight loss, improved nutritional status, and enhanced exercise capacity. This effect may have cardioprotective implications [15, 16].

Tirzepatide Benefits from Clinical Trials

While tirzepatide is already approved as an effective treatment for type 2 diabetes, ongoing clinical trials are exploring its weight loss and cardioprotective benefits.

Tirzepatide and Weight Loss

Tirzepatide’s ability to promote weight loss may be partially explained by its activation of GIP receptors in fat cells. This action leads to reduced adipose tissue inflammation, increased adiponectin levels, and enhanced energy expenditure—all factors associated with reduced fat cell differentiation and improved fat metabolism [1, 17].

Given the global obesity crisis and limited treatment options available, Eli Lilly (the patent holder) launched a clinical program to explore tirzepatide’s potential for weight management. Known as the SURMOUNT program, this initiative includes four phase 3 global trials designed to evaluate tirzepatide as an adjunct to weight loss treatment in adults with a BMI ≥ 27 [6].

In the first trial, which enrolled over 2,500 participants, tirzepatide demonstrated impressive weight loss efficacy. After 72 weeks of treatment, the average weight reductions were as follows:

• 16% for tirzepatide 5mg/week
• 21.4% for tirzepatide 10mg/week
• 22.5% for tirzepatide 15mg/week [6, 7].

The remaining trials are expected to conclude in 2023, further solidifying tirzepatide’s potential as a weight management treatment.

Tirzepatide as a Type 2 Diabetes Treatment

Tirzepatide’s dual action on both GLP-1 and GIP receptors distinguishes it from other treatments for type 2 diabetes [3, 5].

Researchers believe its unique mechanism—mimicking native GIP at the GIP receptor while preferentially activating cAMP signaling at the GLP-1 receptor—underpins its superior efficacy in managing blood glucose levels and promoting insulin secretion [9].

In direct comparisons, tirzepatide has shown greater efficacy than other diabetes medications like semaglutide and dulaglutide, both in terms of glycemic control and weight loss. For example, tirzepatide was more effective than semaglutide at lowering hemoglobin A1c and promoting weight loss in patients with T2D [11, 18].

As a result, the USFDA approved tirzepatide as an adjunct treatment to improve blood sugar control in adults with type 2 diabetes, in combination with diet and exercise [4].

Tirzepatide and Cardioprotective Benefits

Research into GLP-1 suggests that it plays a pivotal role in directly regulating risk factors for cardiovascular disease, such as hypertension and obesity, while indirectly improving inflammation and endothelial dysfunction. As a dual agonist, tirzepatide’s selective targeting of the GLP-1 receptor could help reduce the development of cardiovascular complications, particularly in patients with diabetes [19].

In a 26-week study involving T2D patients, once-weekly tirzepatide injections improved lipoprotein biomarkers related to insulin resistance and cardiovascular risk, while also lowering triglyceride levels. These findings suggest a reduced risk of heart disease for patients treated with tirzepatide [20].

A cardiovascular outcomes study is currently underway to provide further evidence of tirzepatide’s cardioprotective effects, comparing it to the GLP-1 receptor agonist dulaglutide [21].

References

1. Pirro V, Roth KD, Lin Y, Willency JA, Milligan PL, Wilson JM, Ruotolo G, Haupt A, Newgard CB, Duffin KL. Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes. J Clin Endocrinol Metab. 2022 Jan 18;107(2):363-378. doi: 10.1210/clinem/dgab722. PMID: 34608929.
2. Min T, Bain SC. The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials. Diabetes Ther. 2021 Jan;12(1):143-157. doi: 10.1007/s13300-020-00981-0. Epub 2020 Dec 15. PMID: 33325008; PMCID: PMC7843845.
3. Tate M, Chong A, Robinson E, Green BD, Grieve DJ. Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes. Br J Pharmacol. 2015;172(3):721-736. doi:10.1111/bph.12943
4. Wilson, JM, Nikooienejad, A, Robins, DA, et al. The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes. Diabetes Obes Metab. 2020; 22: 2451– 2459.
5. National Library of Medicine (U.S.). (2020, May 29 – ). A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CVOT). Identifier NCT04255433. https://www.clinicaltrials.gov/ct2/show/NCT04255433
6. Frías JP. Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes. Expert Rev Endocrinol Metab. 2020 Nov;15(6):379-394. doi: 10.1080/17446651.2020.1830759. Epub 2020 Oct 8. PMID: 33030356.
7. Ludvik B, Giorgino F, Jódar E, Frias JP, Fernández Landó L, Brown K, Bray R, Rodríguez Á. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021 Aug 14;398(10300):583-598. doi: 10.1016/S0140-6736(21)01443-4. Epub 2021 Aug 6. PMID: 34370970.
8. Bhagavathula AS, Vidyasagar K, Tesfaye W. Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Phase II/III Trials. Pharmaceuticals (Basel). 2021;14(10):991. Published 2021 Sep 28. doi:10.3390/ph14100991.
9. Frias JP, Nauck MA, Van J, Benson C, Bray R, Cui X, Milicevic Z, Urva S, Haupt A, Robins DA. Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens. Diabetes Obes Metab. 2020 Jun;22(6):938-946. doi: 10.1111/dom.13979. Epub 2020 Feb 11. PMID: 31984598; PMCID: PMC7318331.
10. Thomas MK, Nikooienejad A, Bray R, Cui X, Wilson J, Duffin K, Milicevic Z, Haupt A, Robins DA. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. J Clin Endocrinol Metab. 2021 Jan 23;106(2):388-396. doi: 10.1210/clinem/dgaa863. PMID: 33236115; PMCID: PMC7823251.
11. Rosenstock J, Wysham C, Frías JP, Kaneko S, Lee CJ, Fernández Landó L, Mao H, Cui X, Karanikas CA, Thieu VT. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021 Jul 10;398(10295):143-155. doi: 10.1016/S0140-6736(21)01324-6. Epub 2021 Jun 27. Erratum in: Lancet. 2021 Jul 17;398(10296):212. PMID:
12. Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, Aizenberg D, Wynne AG, Riesmeyer JS, Heine RJ, Wiese RJ; SURPASS-4 Investigators. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021 Nov 13;398(10313):1811-1824. doi: 10.1016/S0140-6736(21)02188-7. Epub 2021 Oct 18. PMID: 34672967.
13. Müller TD, Finan B, Bloom SR, D’Alessio D, Drucker DJ, Flatt PR, Fritsche A, Gribble F, Grill HJ, Habener JF, Holst JJ, Langhans W, Meier JJ, Nauck MA, Perez-Tilve D, Pocai A, Reimann F, Sandoval DA, Schwartz TW, Seeley RJ, Stemmer K, Tang-Christensen M, Woods SC, DiMarchi RD, Tschöp MH. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019 Dec;30:72-130. doi: 10.1016/j.molmet.2019.09.010. Epub 2019 Sep 30. PMID: 31767182; PMCID: PMC6812410.
14. Frias JP, Nauck MA, Van J, Kutner ME, Cui X, Benson C, Urva S, Gimeno RE, Milicevic Z, Robins D, Haupt A. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 2018 Nov 17;392(10160):2180-2193. doi: 10.1016/S0140-6736(18)32260-8. Epub 2018 Oct 4. PMID: 30293770.
15. Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, Cui X, Briere DA, Cabrera O, Roell WC, Kuchibhotla U, Moyers JS, Benson CT, Gimeno RE, D’Alessio DA, Haupt A. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018 Dec;18:3-14. doi: 10.1016/j.molmet.2018.09.009. Epub 2018 Oct 3. PMID: 30473097; PMCID: PMC6308032.
16. Dahl D, Onishi Y, Norwood P, Huh R, Bray R, Patel H, Rodríguez Á. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022 Feb 8;327(6):534-545. doi: 10.1001/jama.2022.0078. PMID: 35133415; PMCID: PMC8826179.
17. Heise T, Mari A, DeVries JH, Urva S, Li J, Pratt EJ, Coskun T, Thomas MK, Mather KJ, Haupt A, Milicevic Z. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Lancet Diabetes Endocrinol. 2022 Apr 22:S2213-8587(22)00085-7. doi: 10.1016/S2213-8587(22)00085-7. Epub ahead of print. PMID: 35468322.
18. Furihata K, Mimura H, Urva S, Oura T, Ohwaki K, Imaoka T. A phase 1 multiple-ascending dose study of tirzepatide in Japanese participants with type 2 diabetes. Diabetes Obes Metab. 2022 Feb;24(2):239-246. doi: 10.1111/dom.14572. Epub 2021 Nov 18. PMID: 34647404.